NOACs may do less harm to kidneys than warfarin

Print Friendly, PDF & Email


Warfarin tablet
Photo courtesy of
Intermountain Medical Center
New research suggests warfarin may produce worse renal outcomes than non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation. In a study of close to 10,000 patients, dabigatran and rivaroxaban were associated with lower risks of adverse renal outcomes than warfarin. However, risks... [Read Article]
Print Friendly, PDF & Email

Product approved to treat patients with hemophilia A and inhibitors

Print Friendly, PDF & Email


Emicizumab (Hemlibra)
Photo from Business Wire
The US Food and Drug Administration (FDA) has approved use of emicizumab-kxwh (Hemlibra®), a bispecific factor IXa- and factor X-directed antibody. Emicizumab is approved as routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children who have hemophilia A and factor VIII... [Read Article]
Print Friendly, PDF & Email

CHMP backs therapy for hemophilia A

Print Friendly, PDF & Email


Antihemophilic factor
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for rurioctocog alfa pegol (Adynovi). Rurioctocog alfa pegol (formerly BAX 855) is a pegylated, full-length, recombinant factor VIII product built on a licensed recombinant factor VIII product (Advate). The CHMP is recommending that rurioctocog alfa... [Read Article]
Print Friendly, PDF & Email

Product can improve joint health in hemophilia A

Print Friendly, PDF & Email


Antihemophilic factor
New research suggests prophylaxis with a recombinant factor VIII Fc fusion protein (rFVIIIFc) can improve joint health over time in patients with hemophilia A. Patients saw continuous improvement in joint health over a nearly 3-year period, regardless of prior treatment regimen, severity of joint damage, or target joints. “Gradual joint destruction,... [Read Article]
Print Friendly, PDF & Email

Gene therapy granted breakthrough designation

Print Friendly, PDF & Email


Red blood cells
The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to valoctocogene roxaparvovec (formerly BMN 270) for the treatment of patients with hemophilia A. Valoctocogene roxaparvovec is a recombinant adeno-associated virus vector coding for human coagulation factor VIII (FVIII). The breakthrough designation is intended to expedite the development and... [Read Article]
Print Friendly, PDF & Email